Related Experiment Video

Updated: Nov 24, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.9K

Nivolumab activity in advanced refractory malignant peritoneal mesothelioma

Ondine Becker1, Clément Beaulaton2, Julien Masliah-Planchon3

  • 1Department of Medical Oncology, Institut Curie, PSL Research University, Paris, 75248, France.

European Journal of Cancer (Oxford, England : 1990)
|December 28, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
ImmunotherapyMalignant peritoneal mesotheliomaNext generation sequencingNivolumab

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.1K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K